TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,628 | -55.7% | 171,115 | -35.1% | 0.01% | -57.1% |
| Q1 2023 | $5,926 | +67.8% | 263,499 | +56.9% | 0.01% | +55.6% |
| Q4 2022 | $3,532 | -99.9% | 167,937 | +1.5% | 0.01% | -18.2% |
| Q3 2022 | $4,079,000 | +8.2% | 165,534 | +6.4% | 0.01% | +10.0% |
| Q2 2022 | $3,770,000 | -20.2% | 155,574 | -15.1% | 0.01% | +11.1% |
| Q1 2022 | $4,722,000 | -17.1% | 183,253 | -0.1% | 0.01% | -18.2% |
| Q4 2021 | $5,694,000 | -10.7% | 183,440 | -30.2% | 0.01% | -15.4% |
| Q3 2021 | $6,373,000 | +3.3% | 262,792 | +6.4% | 0.01% | -7.1% |
| Q1 2021 | $6,167,000 | +37.6% | 247,011 | +50.3% | 0.01% | +40.0% |
| Q4 2020 | $4,481,000 | – | 164,383 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |